{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:17:18Z","timestamp":1790414238508,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2816,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To assess the risk of liver function test (LFT) abnormalities with the use of 3\u2010hydroxy\u20103\u2010methylglutaryl coenzyme A reductase inhibitors (statins) for the treatment of hyperlipidemia.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Meta\u2010analysis of randomized, placebo\u2010controlled trials of statins used for the treatment of hyperlipidemia or for primary or secondary prevention of cardiovascular disease.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> University research center.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> A total of 49,275 patients from 13 trials.<\/jats:p><jats:p><jats:bold>Intervention.<\/jats:bold> A literature search of published clinical trials was performed in MEDLINE (January 1966\u2013March 2003) and the Cochrane Controlled Trials Registry (first quarter 2003). Studies also were identified from the references of the trials and of published systematic reviews.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> For a trial to be included in the meta\u2010analysis, its duration of follow\u2010up had to be at least 48 weeks and the trial had to include at least 400 patients, with at least 200 treated with a statin. Trials conducted in transplant recipients were excluded. The proportion of patients having LFT abnormalities was low in both groups (statins 1.14% vs placebo 1.05%, odds ratio [OR] 1.26, 95% confidence interval [CI] 0.99\u20131.62, p=0.07). Only fluvastatin was associated with a significant increase in the odds of having LFT abnormalities (fluvastatin 1.13% vs placebo 0.29%, OR 3.54, 95% CI 1.1\u201311.6, p=0.04) compared with placebo, although this finding was based on only two trials.<\/jats:p><jats:p><jats:bold>Conclusions.<\/jats:bold> Our results support previous observations that pravastatin, lovastatin, and simvastatin at low\u2010to\u2010moderate doses are not associated with a significant risk of LFT abnormalities. Additional data are required to determine whether other statins have a similar safety profile.<\/jats:p>","DOI":"10.1592\/phco.24.6.584.34738","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T11:20:59Z","timestamp":1086952859000},"page":"584-591","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":168,"title":["Statins and Liver Toxicity: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"24","author":[{"given":"Simon","family":"de Denus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Spinler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","volume-title":"Integrated management of cardiovascular risk","author":"Anonymous.","year":"2002"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1592\/phco.22.11.853.33623","article-title":"New cholesterol guidelines, new treatment challenges","volume":"22","author":"McKenney J.M.","year":"2002","journal-title":"Pharmacotherapy"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0002-9343(86)90158-0","article-title":"Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on the primary screenees of the multiple risk factor intervention trial","volume":"80","author":"Stamler J.","year":"1986","journal-title":"Am J Med"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas coronary atherosclerosis prevention study","volume":"279","author":"Downs J.R.","year":"1998","journal-title":"JAMA"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group","volume":"333","author":"Shepherd J.","year":"1995","journal-title":"N Engl J Med"},{"key":"e_1_2_1_7_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group.","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long\u2010Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks F.M.","year":"1996","journal-title":"N Engl J Med"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high\u2010risk individuals: a randomised placebo\u2010controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group.","year":"2002","journal-title":"Lancet"},{"key":"e_1_2_1_11_2","first-page":"60","article-title":"Top 200 brand\u2010name drugs by units in 2002","volume":"6","author":"Anonymous.","year":"2003","journal-title":"Drug Top"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.","year":"2001","journal-title":"JAMA"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1345\/aph.1A413","article-title":"Early statin therapy for acute coronary syndromes","volume":"36","author":"Denus S.","year":"2002","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_14_2","first-page":"567","article-title":"American College of Cardiology\/American Heart Association\/National Heart, Lung, and Blood Institute clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak R.C.","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_15_2","unstructured":"Merck and Co. Inc.Mevacor (lovastatin) package insert. Whitehouse Station NJ;2002."},{"key":"e_1_2_1_16_2","unstructured":"Novartis Pharmaceuticals Canada Inc.Lescol (fluvastatin) package insert. Dorval Quebec;2002."},{"key":"e_1_2_1_17_2","unstructured":"Pfizer Inc.Lipitor (atorvastatin) package insert. New York NY;2002."},{"key":"e_1_2_1_18_2","unstructured":"Bristol\u2010Myers Company.Pravachol (pravastatin) package insert. Princeton NJ;2003."},{"key":"e_1_2_1_19_2","unstructured":"Merck and Co. Inc.Zocor (simvastatin) package insert. Whitehouse Station NJ;2003."},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0002-9149(02)02590-0","article-title":"Getting more people on statins","volume":"90","author":"Roberts W.C.","year":"2002","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin","volume":"89","author":"Tolman K.G.","year":"2002","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archinte.163.6.688","article-title":"Screening for statin\u2010related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting","volume":"163","author":"Smith C.C.","year":"2003","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford R.H.","year":"1991","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG\u2010CoA reductase inhibitors","volume":"35","author":"Omar M.A.","year":"2001","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/01.CIR.90.4.1679","article-title":"Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPS) research group","volume":"90","author":"Furberg C.D.","year":"1994","journal-title":"Circulation"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly: results of the cholesterol reduction in seniors program (CRISP) pilot study","volume":"154","author":"LaRosa J.C.","year":"1994","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.eurheartj.a060485","article-title":"Three\u2010year follow\u2010up of the Oxford cholesterol study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study","volume":"15","author":"Keech A.","year":"1994","journal-title":"Eur Heart J"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/01.CIR.92.7.1758","article-title":"Kuopio atherosclerosis prevention study (KAPS): a population\u2010based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries","volume":"92","author":"Salonen R.","year":"1995","journal-title":"Circulation"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0002-9149(97)00346-9","article-title":"Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS])","volume":"80","author":"Herd J.A.","year":"1997","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys P.W.","year":"2002","journal-title":"JAMA"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd J.","year":"2002","journal-title":"Lancet"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low\u2010dose metoprolol CR\/XL and fluvastatin slow progression of carotid intima\u2010media thickness: main results from the beta\u2010blocker cholesterol\u2010lowering asymptomatic plaque study (BCAPS)","volume":"103","author":"Hedblad B.","year":"2001","journal-title":"Circulation"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","article-title":"Long\u2010term effects of cholesterol lowering and angiotensin\u2010converting enzyme inhibition on coronary atherosclerosis: the simvastatin\/enalapril coronary atherosclerosis trial (SCAT)","volume":"102","author":"Teo K.K.","year":"2000","journal-title":"Circulation"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","article-title":"Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS)","volume":"91","author":"Jukema J.W.","year":"1995","journal-title":"Circulation"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1053\/euhj.2002.3291","article-title":"Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial","volume":"23","author":"Liem A.H.","year":"2002","journal-title":"Eur Heart J"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0735-1097(95)00301-0","article-title":"Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation","volume":"26","author":"Pitt B.","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower\u2010than\u2010average cholesterol concentrations, in the Anglo\u2010Scandinavian cardiac outcomes trial\u2010lipid lowering arm (ASCOT\u2010LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever P.S.","year":"2003","journal-title":"Lancet"},{"key":"e_1_2_1_38_2","first-page":"261","volume-title":"The handbook of research synthesis","author":"Shadish W.R.","year":"1994"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0735-1097(02)01913-7","article-title":"Physicians' interpretation of \u201cclass effects\u201d: a need for thoughtful re\u2010evaluation","volume":"40","author":"Kennedy H.L.","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1345\/aph.1C116","article-title":"Lack of therapeutic interchangeability of HMG\u2010CoA reductase inhibitors","volume":"36","author":"Chong P.H.","year":"2002","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(01)00870-1","article-title":"Clinically relevant differences between the statins: implications for therapeutic selection","volume":"111","author":"Chong P.H.","year":"2001","journal-title":"Am J Med"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa J.A.","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long\u2010term clinical trials: prospective pravastatin pooling (PPP) project","volume":"105","author":"Pfeffer M.A.","year":"2002","journal-title":"Circulation"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","article-title":"Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol\u2010lowering activity of (\u2010)\u20103S, 5R\u2010fluvastatin and (+)\u20103R, 5S\u2010fluvastatin in healthy volunteers","volume":"74","author":"Kirchheiner J.","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_45_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.tpj.6500144","article-title":"Cytochrome P450 3A pharmacogenetics: the road that needs traveled","volume":"3","author":"Flockhart D.A.","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinte.163.6.657","article-title":"Safety and statin therapy: reconsidering the risks and benefits","volume":"163","author":"Gotto A.M.","year":"2003","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study\u2014a randomized controlled trial","volume":"285","author":"Schwartz G.G.","year":"2001","journal-title":"JAMA"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid\u2010lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen S.E.","year":"2004","journal-title":"JAMA"},{"issue":"15","key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon C.P.","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_1_50_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta\u2010analysis of all major randomised clinical trials","volume":"359","author":"Boersma E.","year":"2002","journal-title":"Lancet"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.24.6.584.34738","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.24.6.584.34738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:42:34Z","timestamp":1761054154000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.24.6.584.34738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1592\/phco.24.6.584.34738"],"URL":"https:\/\/doi.org\/10.1592\/phco.24.6.584.34738","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}